SI1059931T1 - Utilization of cd137 in order to promote the proliferation of peripheral monocytes - Google Patents

Utilization of cd137 in order to promote the proliferation of peripheral monocytes

Info

Publication number
SI1059931T1
SI1059931T1 SI9930165T SI9930165T SI1059931T1 SI 1059931 T1 SI1059931 T1 SI 1059931T1 SI 9930165 T SI9930165 T SI 9930165T SI 9930165 T SI9930165 T SI 9930165T SI 1059931 T1 SI1059931 T1 SI 1059931T1
Authority
SI
Slovenia
Prior art keywords
utilization
proliferation
order
promote
peripheral monocytes
Prior art date
Application number
SI9930165T
Other languages
English (en)
Slovenian (sl)
Inventor
Herbert Schwarz
Joachim Langstein
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of SI1059931T1 publication Critical patent/SI1059931T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SI9930165T 1998-07-15 1999-03-05 Utilization of cd137 in order to promote the proliferation of peripheral monocytes SI1059931T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15
EP99910331A EP1059931B1 (fr) 1998-07-15 1999-03-05 Utilisation du facteur cd137 pour la stimulation de la proliferation de monocytes peripheriques
PCT/EP1999/001440 WO1999044629A2 (fr) 1998-03-05 1999-03-05 Utilisation du facteur cd137 pour la stimulation de la proliferation de monocytes peripheriques

Publications (1)

Publication Number Publication Date
SI1059931T1 true SI1059931T1 (en) 2003-04-30

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930165T SI1059931T1 (en) 1998-07-15 1999-03-05 Utilization of cd137 in order to promote the proliferation of peripheral monocytes

Country Status (21)

Country Link
US (1) US6627200B1 (fr)
EP (1) EP1059931B1 (fr)
JP (1) JP2003521439A (fr)
KR (1) KR20010041624A (fr)
AT (1) ATE228371T1 (fr)
AU (1) AU747063B2 (fr)
BR (1) BR9908518A (fr)
CA (1) CA2322684A1 (fr)
CZ (1) CZ20003238A3 (fr)
DE (1) DE59903541D1 (fr)
DK (1) DK1059931T3 (fr)
EE (1) EE200000510A (fr)
ES (1) ES2188140T3 (fr)
HU (1) HUP0102046A3 (fr)
IS (1) IS1986B (fr)
NO (1) NO20004393L (fr)
NZ (1) NZ506695A (fr)
PL (1) PL343427A1 (fr)
PT (1) PT1059931E (fr)
SI (1) SI1059931T1 (fr)
WO (1) WO1999044629A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031474A2 (fr) * 2001-10-04 2003-04-17 Herbert Schwarz Cd137 en tant que facteur de proliferation pour cellules souches hematopoietiques
EP1545578A4 (fr) * 2002-08-28 2010-07-07 Immunex Corp Compositions et procedes de traitement de maladies cardio-vasculaires
EP1575672A2 (fr) * 2002-12-16 2005-09-21 Herbert Schwarz Utilisation d'antagonistes de cd137 pour le traitement de tumeurs
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5861191B2 (ja) * 2010-09-30 2016-02-16 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
WO2014165452A1 (fr) * 2013-04-03 2014-10-09 The Regents Of The University Of California Compositions et procédés d'inhibition de l'activité virale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
WO1994026290A1 (fr) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine denommee ligand 4-1bb et recepteur humain s'y fixant
JPH09503911A (ja) * 1993-09-16 1997-04-22 インディアナ・ユニバーシティー・ファウンデーション ヒトｈ４−１ｂｂ受容体
CA2108401A1 (fr) * 1993-09-27 1995-03-28 Martin Lotz Recepteur induit par l'activation de lymphocytes dans la reaction inflammatoire

Also Published As

Publication number Publication date
AU747063B2 (en) 2002-05-09
EP1059931B1 (fr) 2002-11-27
ES2188140T3 (es) 2003-06-16
US6627200B1 (en) 2003-09-30
NO20004393L (no) 2000-10-31
PT1059931E (pt) 2003-04-30
HUP0102046A2 (hu) 2001-10-28
BR9908518A (pt) 2000-11-21
DE59903541D1 (de) 2003-01-09
CA2322684A1 (fr) 1999-09-10
KR20010041624A (ko) 2001-05-25
CZ20003238A3 (cs) 2001-10-17
NZ506695A (en) 2005-01-28
PL343427A1 (en) 2001-08-13
NO20004393D0 (no) 2000-09-04
HUP0102046A3 (en) 2006-02-28
EE200000510A (et) 2002-02-15
AU2932499A (en) 1999-09-20
DK1059931T3 (da) 2003-03-24
WO1999044629A3 (fr) 2000-01-06
ATE228371T1 (de) 2002-12-15
WO1999044629A2 (fr) 1999-09-10
IS1986B (is) 2005-02-15
EP1059931A2 (fr) 2000-12-20
JP2003521439A (ja) 2003-07-15
IS5613A (is) 2000-08-30

Similar Documents

Publication Publication Date Title
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
NO20021281L (no) Vaskul¶r beleggingssammensetning
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DE60014966D1 (de) Behandlung zur vermeidung von kalzifizierung für fixierte biomaterialien
DE69939864D1 (de) Ppar-gamma modulatoren
MY124214A (en) Compositions for promoting crowth
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
MY121031A (en) Process for preparing derivatives of the taxoid family
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
CA2391098A1 (fr) .alpha.-iduronidase recombinante, procede de preparation et de purification de celle-ci et methodes de traitement des maladies causees par des deficiences de celle-ci
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
HK1008347A1 (en) Dorsal tissue affecting factor and compositions
BR9813778A (pt) Utilização de pelo menos um fucano.
ATE285177T1 (de) Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen
PL343427A1 (en) Utilization of cd137 in order to promote the proliferation of peripheral monocytes
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
WO2000066732A3 (fr) Laminine 8 et ses procedes d'utilisation
BG105779A (en) Human antibiotic proteins
MY120530A (en) Combination preparation for use in dementia
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
ITMI20000564A0 (it) Impianto di trattamento per substrati piatti
PT1196606E (pt) Enzima litica
GB9723266D0 (en) Improvements relating to treatment vessels, for example for the acetylation of lignocellulosic fibres
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь